Triethylamine → HCID 68228514, 화합물
반응식
Cl.[NH2:2][CH2:3][C:4]1[CH:5]=[CH:6][C:7]([F:39])=[C:8]([CH:10]2[CH2:15][CH2:14][N:13]([C:16]([C:18]3[C:26]4[C:21](=[CH:22][CH:23]=[CH:24][C:25]=4[C:27]([N:29]4[CH2:34][CH2:33][O:32][CH2:31][CH2:30]4)=[O:28])[N:20]([CH2:35][CH2:36][O:37][CH3:38])[CH:19]=3)=[O:17])[CH2:12][CH2:11]2)[CH:9]=1.OC1C2N=NNC=2C=CC=1.[NH:50]([C:62]([O:64][C:65]([CH3:68])([CH3:67])[CH3:66])=[O:63])[C@H:51]([C:55]([NH:57][CH2:58][C:59](O)=[O:60])=[O:56])[CH:52]([CH3:54])[CH3:53].C(N(CC)CC)C.Cl.CN(C)CCCN=C=NCC>CN(C=O)C.C(OCC)(=O)C>[C:65]([O:64][C:62](=[O:63])[NH:50][CH:51]([C:55](=[O:56])[NH:57][CH2:58][C:59](=[O:60])[NH:2][CH2:3][C:4]1[CH:5]=[CH:6][C:7]([F:39])=[C:8]([CH:10]2[CH2:15][CH2:14][N:13]([C:16]([C:18]3[C:26]4[C:21](=[CH:22][CH:23]=[CH:24][C:25]=4[C:27]([N:29]4[CH2:34][CH2:33][O:32][CH2:31][CH2:30]4)=[O:28])[N:20]([CH2:35][CH2:36][O:37][CH3:38])[CH:19]=3)=[O:17])[CH2:12][CH2:11]2)[CH:9]=1)[CH:52]([CH3:53])[CH3:54])([CH3:66])([CH3:68])[CH3:67]참가 물질
반응물 5
생성물 1
시약·촉매·용매 2
반응 조건
- 온도
- 0 °C
실험 절차
[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indol-3-yl]-methanone hydrochloride (100 mg, 0.18 mmol) was dissolved in DMF (2.6 mL) under nitrogen and stirred at 0° C. for 5 min. To this was added sequentially hydroxybenzotriazole (77 mg, 0.57 mmol), BOC-Val-Gly-OH (59 mg, 0.21 mmol), triethylamine (0.05 mL, 0.36 mmol) followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (41 mg, 0.21 mmol). The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with brine (30 mL). The brine was back extracted with ethyl acetate (2×30 mL) and the organic fractions were combined and washed with 10% citric acid (2×30 mL), sat sodium bicarbonate solution (2×30 mL) and brine (30 mL). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to give the crude product which was purified by SiO2 column chromatography using 5% MeOH/CH2Cl2 as the eluent to afford (1-{[(4-fluoro-3-{1-[1-(2-methoxy-ethyl)-4-(morpholine-4-carbonyl)-1H-indole-3-carbonyl]-piperidin-4-yl}-benzylcarbamoyl)-methyl]-carbamoyl}-2-methyl-propyl)-carbamic acid tert-butyl ester (100 mg, 72%). 1H NMR (300 MHz, CDCl3) δ 7.40-7.30 (m, 2H), 7.28-7.21 (m, 2H), 7.18-7.10 (m, 1H), 7.08-7.00 (m, 1H), 6.98-6.85 (m, 1H), 5.00-4.90 (br s, 1H), 4.30 (t, 2H), 3.85-3.70 (br m, 2H), 3.73 (t, 2H), 3.47 (s, 2H), 3.33 (s, 3H), 3.20-2.90 (br m, 2H), 1.90-1.60 (br m, 6H), 1.30-1.24 (m, 10H), 1.80-1.70 (br m, 6H); 19F NMR (282 MHz, CDCl3) δ −57.60 (s, 1F); MS m/z: [M+H]+=779.
후처리
- temperatureThe reaction mixture was warmed to room temperature
- stirringstirred overnight
- washwashed with brine (30 mL)
- extractionThe brine was back extracted with ethyl acetate (2×30 mL)
- washwashed with 10% citric acid (2×30 mL)
- dry with materialThe organic layer was dried over sodium sulfate
- filtrationfiltered
- concentrationconcentrated in vacuo
- customto give the crude product which
- customwas purified by SiO2 column chromatography
출처 및 근거
- ORD 기록
- ord-e811c860f298484684cf147bd7128259
- 출처 데이터셋
- uspto-grants-2014_04
- 특허 번호
- US08710080B2
반응 노트
불러오는 중…